ZTS Quantitative Stock Analysis

According to Validea's guru fundamental report, ZOETIS INC (ZTS) receives an 82% rating based on Warren Buffett's Patient Investor strategy, which favors firms with predictable profitability, low debt, and reasonable valuations; the report indicates strong performance on earnings predictability, debt service, return on equity, free cash flow, use of retained earnings, share repurchase, initial rate of return, and expected return, but it fails on return on total capital.

Analysis

Zoetis Inc. (ZTS) has achieved an 82% rating under Validea's Patient Investor model, which is based on Warren Buffett's strategy emphasizing firms with long-term, predictable profitability, low debt, and reasonable valuations. According to the model's scoring, an 82% rating typically indicates that the strategy has "some interest" in the stock. ZTS, a large-cap growth stock in the Biotechnology & Drugs industry, passed crucial tests for earnings predictability, debt service, return on equity, free cash flow, use of retained earnings, share repurchase, initial rate of return, and expected return. However, the company failed the "Return on Total Capital" criterion, a point of divergence from the model's ideal profile. This specific analysis by Validea carries a strongly positive sentiment for ZTS, underscoring its fundamental appeal according to this particular investment framework.

Key Decisions for Investors

• Given ZTS's alignment with multiple Buffett-style fundamental criteria, investors seeking long-term, quality growth could consider it for further due diligence.
• The specific failure on the 'Return on Total Capital' metric requires careful examination to assess its potential impact on overall capital efficiency and future returns.
• Despite the positive evaluation on several fronts, including earnings predictability and share repurchases, understanding the context of the single failed metric is crucial before making investment decisions.